Skip to main content

Table 2 Interacting kinetics of bevacizumab and FD006 binding to VEGF

From: Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization

 

KD (M)

Kon (1/Ms)

Kdis (1/s)

Full R2

bevacizumab

6.50E-10

1.75E + 05

1.02E-04

0.992536

FD006

3.11E-10

1.48E + 05

4.59E-05

0.992964

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us